Evidence map›Paper›PMID 20041868›Full record

ReviewAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2010

Beta-lactam antibiotics: from antibiosis to resistance and bacteriology.

Kok-Fai Kong, Lisa Schneper, Kalai Mathee

Abstract readReview
In one paragraph

Review in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Tazobactam selects for multidrug resistance.npj antimicrobials and resistance · 2025
    Article
  12. Article
  13. Beta-lactam combination treatment overcomes rifampicin resistance in Mycobacterium tuberculosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Conjugation of Polycationic Peptides Extends the Efficacy Spectrum of β-Lactam Antibiotics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  19. Article
  20. Review

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kok-Fai KongDepartment of Biological Sciences, Florida International University, Miami, FL, USA.
Lisa Schneper
Kalai Mathee

Funding

Theaflavins and Gallic Acid in TeaS06GM008205 · NIGMS · FLORIDA INTERNATIONAL UNIVERSITY · PI BIGGER, CHARLES H · 1989 to 2008
$17.6M
Regulation of P. aeruginosa PoxB Oxacillinase by AmpR and a Two-Component SystemSC1AI081376 · NIAID · FLORIDA INTERNATIONAL UNIVERSITY · PI MATHEE, KALAI · 2008 to 2011
$1.2M
NIAID NIH HHS 5SC1AI081376NIAID NIH HHS SC1 AI081376NIGMS NIH HHS S06 GM008205NIGMS NIH HHS S06 GM08205
6 · The paper itself

Abstract

This review focuses on the era of antibiosis that led to a better understanding of bacterial morphology, in particular the cell wall component peptidoglycan. This is an effort to take readers on a tour de force from the concept of antibiosis, to the serendipity of antibiotics, evolution of beta-lactam development, and the molecular biology of antibiotic resistance. These areas of research have culminated in a deeper understanding of microbiology, particularly in the area of bacterial cell wall synthesis and recycling. In spite of this knowledge, which has enabled design of new even more effective therapeutics to combat bacterial infection and has provided new research tools, antibiotic resistance remains a worldwide health care problem.

Indexed as

AntibiosisAnti-Bacterial AgentsBacteriabeta-Lactam Resistancebeta-LactamsCell WallAnti-Bacterial Agentsbeta-Lactams

Identifiers

PMID20041868
PMCPMC2894812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.